Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer

Tissue Antigens

Volumn 60, Issue 3, 2002, Pages 235-243

  McEvoy, Chris R E ^a,b   Seshadri, R ^a   Morley, A A ^a   Firgaira, Frank A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

2m; HLA class I; Immune escape; Loss of heterozygosity; MEMO 1; Microsatellite markers; Tumor

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; MICROSATELLITE DNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER GRADING; CHROMOSOME 15Q; CHROMOSOME 1P; CHROMOSOME 6; CHROMOSOME 6P; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMO 1 GENE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; BREAST TUMOR; CHROMOSOME 1; COHORT ANALYSIS; DNA METHYLATION; FEMALE; GENETICS; IMMUNOLOGY;

BETA 2-MICROGLOBULIN; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 6; COHORT STUDIES; DNA METHYLATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS;

EID: 0036760077     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600305.x     Document Type: Article

References (42)

1. Cabrera T, Fernandez MA, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996: 50: 127-34.
2. Pistillo MP, Nicola G, Salvi S et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol 2000: 61: 397-407.
3. Gudmundsdóttir I, Jónasson JG, Sigurdsson H, Olafsdóttir K, Tryggvadóttir L, Ogmundsdóttir HM. Altered expression of HLA class I antigens in breast cancer: Association with prognosis. Int J Cancer (Pred Oncol) 2000: 89: 500-5.
4. Redondo M, Concha A, Ruiz-Cabello F et al. Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas. Cancer Detect Prev 1997: 21: 22-8.
5. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001: 91: 109-19.
6. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the beta-2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998: 52: 520-9.
7. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996: 88: 100-8.
8. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered class I phenotypes in human tumours. Immunol Today 1997: 18: 89-95.
9. Brady CS, Bartholomew JS, Burt DJ et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000: 55: 401-11.
10. Koopman LA, Corver WE, van der Silk AR, Giphart MJ, Jan Fleuren G. Multiple genetic alterations cause frequent and heterogeneous human leukocyte antigen class I loss in cervical cancer. J Exp Med 2000: 191: 961-76.
11. Garrido F. HLA and cancer. Tissue Antigens 1996: 47: 361-3.
12. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: CDC27 as a tumor antigen. Science 1999: 284: 1351-4.
13. Bicknell DC, Rowan A, Bodmer WF. β2-microglobulin gene mutations: A study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994: 91: 4751-5.
14. Cheng NC, Chan AJK, Beitsma MM, Speleman F, Westerveld A, Versteeg R. A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands 1p35-36.1. Hum Mol Genet 1996: 5: 309-17.
15. Cheng NC, Beitsma M, Chan A et al. Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. Oncogene 1996: 13: 1737-44.
16. Jiménez P, Canton J, Collado A et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumours. Int J Cancer 1999: 83: 91-7.
17. Metzelaar-Blok J, Jager MJ, Moghaddam PH, van der Silk AR, Giphart MJ. Frequent loss of heterozygosity on chromosome 6p in uveal melanoma. Hum Immunol 1999: 60: 962-9.
18. Feenstra M, Veltkamp M, van Kuik J et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999: 54: 235-45.
19. Mazurenko N, Attaleb M, Gritsko T et al. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep 1999: 6: 859-63.
20. Riemersma SA, Jordanova ES, Schop R et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000: 96: 3569-77.
21. Torres MJ, Ruiz-Cabello F. Skoudy A et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumour derived cell line. Tissue Antigens 1996: 47: 372-81.
22. Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993: 67: 551-9.
23. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993: 11: 1936-42.
24. Firgaira FA, Male DA, Morley AA. The ancestral HLA-A lineage split is delineated by an intron 3 insertion/deletion polymorphism. Immunogenetics 1994: 40: 445-8.
25. Carrington M, Dean M. A polymorphic dinucleotide repeat in the third intron of TAP1. Hum Mol Genet 1994: 3: 218.
26. Tamiya G, Ota M, Katsuyama Y et al. Twenty-six new polymorphic microsatellite markers around the HLA-B-C and -E loci in the human MHC class I region. Tissue Antigens 1998: 51: 337-46.
27. Beck S, Abdulla S, Alderton RP et al. Evolutionary dynamics of non-coding sequences within the class II region of the MHC. J Mol Biol 1996: 255: 1-13.
28. Gyapay G, Morisette J, Vignal A et al. The 1993-94 Genethon human genetic linkage map. Nature Genet 1994: 7: 246-339.
29. Polymeropoulos MH, Rath DS, Xiao H, Merril CR. Tetranucleotide repeat polymorphism at the human coagulation factor XIIIA subunit gene (F13A1). Nucl Acids Res 1991: 19: 4306.
30. Smith JR, Carpten JD, Brownstein MJ et al. Approach to genotyping errors caused by nontemplated nucleotide addition by Taq DNA polymerase. Genome Res 1995: 5: 312-7.
31. Ramal LM, Feenstra M, van der Zwan AW et al. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000: 55: 443-8.
32. Yamamoto H, Perez-Piteira J, Yoshida T et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999: 116: 1348-57.
33. Feenstra M, Verdaasdonk M, van der Zwan AW, de Weger R, Slootweeg P, Tilanus M. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Laboratory Invest 2000: 80: 405-14.
34. Bertheau P, Plassa LF, Lerebours F et al. Allelic loss detection in inflammatory breast cancer: Improvement with laser microdissection. Laboratory Invest 2001: 81: 1397-402.
35. Kerangueven F, Noguchi T, Coulier F et al. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997: 57: 5469-74.
36. Shen C-Y, Yu J-C, Lo Y-L et al. Genome-wide search for LOH using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000: 60: 3884-92.
37. Morley AA, Grist SA, Turner DR, Kutlaca A, Bennett G. Molecular nature of in vivo mutations in human cells at the autosomal HLA-A locus. Cancer Res 1990: 50: 4584-7.
38. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995: 14: 227-51.
39. Chen HL, Gabrilovich D, Virmani A et al. Structural and functional analysis of β2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 1996: 67: 756-63.
40. Feenstra M, Rozemuller E, Duran K et al. Mutation in the β2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol 1999: 60: 697-706.
41. Serrano A, Tanzarella S, Lionello I et al. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-AZA-2′-deoxycytidine treatment, lnt J Cancer 2001: 94: 243-51.
42. Nie Y, Yang G, Song Y et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human squamous cell carcinomas. Carcinogenesis 2001: 22: 1615-23.